Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528
Status:
Completed
Trial end date:
2012-03-28
Target enrollment:
Participant gender:
Summary
This open label extension study allows assessment of the long term safety profile of REQUIP
PR in subjects who have completed 24 weeks of randomised treatment in study ROP111528.
Subjects must not have a break in study medication between completing the feeder study and
entering extension study, treatment must be continuous.
Subjects will be dispensed down-titration medication at the study completion/early withdrawal
visit and should be scheduled to return for a follow up visit 4 to 14 days after the last
dose of study medication.